cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-31. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Hydrogen selenide is an extremely toxic, corrosive gas. Selenium also occurs in organic compounds, such as dimethyl selenide, selenomethionine, selenocysteine and methylselenocysteine, all of which have high bioavailability and are toxic in large doses. The Occupational Safety and Health Administration (OSHA) has set the legal limit (permissible exposure limit) for selenium in the workplace at 0.2 mg/m3 over an 8-hour workday. The National Institute for Occupational Safety and Health (NIOSH) has set a Recommended exposure limit (REL) of 0.2 mg/m3 over an 8-hour workday. At levels of 1 mg/m3, selenium is immediately dangerous to life and health.
== External links == "Tiratricol ( Code - C66605 )". EVS Explore. "Tiratricol Sodium ( Code - C218928 )". EVS Explore. Clinical trial number NCT05579327 for "Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) (ReTRIACt)" at ClinicalTrials.gov Clinical trial number NCT02060474 for "Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients" at ClinicalTrials.gov
Combined with a better understanding of female pelvic floor connective tissue, these ideas would go on to influence surgical approaches for the treatment of uterine prolapse. By the early 20th century, different techniques for vaginal hysterectomies had been described and performed. As a result, post-hysterectomy vaginal vault prolapse became more common and a growing concern for some surgeons, and new techniques to correct this complication were attempted. In 1957, Arthure and Savage of London's Charing Cross Hospital, suspecting that uterine prolapse could not be cured with hysterectomy alone, published their surgical technique of sacral hysteropexy. Their technique is still used in modern practice with the addition of a graft.
== Biography == Born at Port Stanley in 1942 to New Zealanders Harold and Moya (née Boak) Baker, he spent his early life in the Falkland Islands, where his father was the superintendent of education. The family returned to New Zealand in 1948. He was educated at King's College, Auckland from 1956 to 1960. After studying chemistry at the University of Auckland, completing his PhD in 1967, he conducted postdoctoral research on the structure of insulin with Nobel laureate Dorothy Hodgkin at the University of Oxford. He then took up an academic post at Massey University, where he determined the structure of the kiwifruit enzyme actinidin. In 1997 he moved back to the University of Auckland where he became professor of structural biology and later direct of the Maurice Wilkins Center for Molecular Diversity. He also served as president of the International Union of Crystallography between 1996 and 1999. Baker was elected a Fellow of the Royal Society of New Zealand in 1987, and won the society's Hector Medal in 1997. He was awarded the Rutherford Medal, the highest honour in New Zealand science, in 2006. In the 2007 Queen's Birthday Honours, he was appointed a Companion of the New Zealand Order of Merit, for services to science.
Sources: en.wikipedia.org
=== 1945–1946 === After the end of the war, Amin al-Husayni managed to find his way to Egypt and stayed there until 1959, when he moved to Lebanon. On 22 March 1945, the Arab League was formed. In November 1945, on the urging of Egypt, its leading member, the then seven members of the Arab League (Lebanon, Syria, Iraq, Jordan, Saudi Arabia, Egypt, and Yemen) reconstituted the Arab Higher Committee comprising twelve members as the supreme executive body of Palestinian Arabs in the territory of the British Mandate of Palestine. The committee was dominated by the Palestine Arab Party, controlled by the Husayni family, and was immediately recognised by Arab League countries. The Mandate government recognised the new committee two months later. In February 1946, Jamal al-Husayni returned from exile to Palestine and immediately set about reorganising and enlarging the committee, becoming its acting president. The members of the reconstituted committee as at April 1946 were:
Using surface electrodes on the body, it is possible to record the electrical activity of the heart. This tracing of the electrical signal is the electrocardiogram (ECG or EKG). An ECG is a bedside test and involves the placement of ten leads on the body. This produces a "12 lead" ECG (three extra leads are calculated mathematically, and one lead is electrically ground, or earthed). There are five prominent features on the ECG: the P wave (atrial depolarisation), the QRS complex (ventricular depolarisation) and the T wave (ventricular repolarisation). As the heart cells contract, they create a current that travels through the heart. A downward deflection on the ECG implies cells are becoming more positive in charge ("depolarising") in the direction of that lead, whereas an upward inflection implies cells are becoming more negative ("repolarising") in the direction of the lead. This depends on the position of the lead, so if a wave of depolarising moved from left to right, a lead on the left would show a negative deflection, and a lead on the right would show a positive deflection. The ECG is a useful tool in detecting rhythm disturbances and in detecting insufficient blood supply to the heart. Sometimes abnormalities are suspected, but not immediately visible on the ECG. Testing when exercising can be used to provoke an abnormality or an ECG can be worn for a longer period such as a 24-hour Holter monitor if a suspected rhythm abnormality is not present at the time of assessment.
=== Opisthoglyphous colubrids === Biologists had long known that some snakes had rear fangs, 'inferior' venom injection mechanisms that might immobilize prey; although a few fatalities were on record, until 1957, the possibility that such snakes were deadly to humans seemed at most remote. The deaths of two prominent herpetologists, Robert Mertens and Karl Schmidt, from African colubrid bites, changed that assessment, and recent events reveal that several other species of rear-fanged snakes have venoms that are potentially lethal to large vertebrates. Boomslang (Dispholidus typus) and twig snake (Thelotornis spp.) venoms are toxic to blood cells and thin the blood (hemotoxic, hemorrhagic). Early symptoms include headaches, nausea, diarrhea, lethargy, mental disorientation, bruising, and bleeding at the site and all body openings. Exsanguination is the main cause of death from such a bite. The boomslang's venom is the most potent of all rear-fanged snakes in the world based on LD50. Although its venom may be more potent than some vipers and elapids, it causes fewer fatalities owing to various factors (for example, the fangs' effectiveness is not high compared with many other snakes, the venom dose delivered is low, and boomslangs are generally less aggressive in comparison to other venomous snakes such as cobras and mambas). Symptoms of a bite from these snakes include nausea and internal bleeding, and one could die from a brain hemorrhage and respiratory collapse.
In 2018 Carlisle played 17 matches (4 wins, 1 draw and 12 losses) with the Saints' rebuild taking a backwards step. Carlisle would have played more games, but was suspended for two matches for striking Richmond's Jack Riewoldt and suffered a punctured lung in another incident after a mistake by club doctors. Carlisle managed only 10 games for the 2019 season due to injury, requiring surgery on his back for a protruding disc prior to the commencement of the season. He eventually returned in round 14 and played 10 consecutive games as the Saints transitioned to new coach Brett Ratten. Carlisle triggered an automatic 1-year contract extension upon reaching a games clause. Carlisle played 13 of a possible 19 games in a COVID-interrupted season, including the Saints' elimination final win against the Western Bulldogs. Carlisle was unable to play in the Saints' semi final game against Richmond due to the birth of his third child. Carlisle signed a further 1-year contract at the end of the year to remain at the club for the 2021 season. Carlisle was not selected for the first two rounds of the year, despite being available. He eventually returned to the side in Round Three, and played four consecutive games including an influential game against Port Adelaide in Round Six. This would consequently be his last AFL match. Carlisle suffered a back complaint during training ahead of Round Seven, and eventually was sent for surgery in mid May.
=== Historical use by government agencies === Beginning in the 1950s, the US Central Intelligence Agency (CIA) began a research program code-named Project MKUltra. The CIA introduced LSD to the United States, purchasing the entire world's supply for $240,000 and propagating the LSD through CIA front organizations to American hospitals, clinics, prisons, and research centers. Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public to study their reactions (usually without the subjects' knowledge), the most well-known example of this being Operation Midnight Climax. The project was revealed in the US congressional Rockefeller Commission report in 1975. However, the extent of the experiments conducted under Project MKUltra are still mostly unknown, as acting CIA director Richard Helms destroyed many of the key documents related to MKUltra in 1973. According to declassified CIA documents, it's possible that the American agency spread LSD amongst civilians in Europe in the 1950s. LSD was also one of several psychoactive substances evaluated by the U.S. Army Chemical Corps as possible non-lethal incapacitants in the Edgewood Arsenal human experiments.
Sources: en.wikipedia.org
Intensity-fading MALDI is a term coined to rename an existing method originally reported in 1999 to indirectly study a Protein–protein interaction or other protein complex and was the same year applied to a biological mixture to study the antigenicity of the influenza virus. It involves treating a protein and a potential binding partner with a site-specific endoproteinase with the binding sites identified by their reduced area (or intensity) in a MALDI mass spectrum compared to that of non-bound protein control. It was falsely reported as new and novel in a later application by a Spanish group. The true origins of the approach and a range of applications including those employing gel based separations, drug-protein interactions and the relative affinity of such interactions, are described in a review article.
== Natural occurrence == Sodium hyaluronate, as hyaluronic acid, is distributed widely in the extracellular matrix of mammalian connective, epithelial, and neural tissues, as well as the corneal endothelium.
== Career == Thomsen worked as a pharmacologist at Leo Pharma from 1989 to 1991 and was thereafter employed by Novo Nordisk in as head of Growth Hormone Research. He became senior vice president for diabetes R&D in 1994 and was appointed senior vice president of Health Care Discovery in 1995. In November 2000, he was appointed executive vice president of Global R&D and chief scientific officer (CSO). As chief scientific officer, he was responsible for the research and development of 20 medicine products within diabetes, obesity and biopharmaceuticals. He led the development of GLP-1 therapies that today are among the leading treatments within type 2 diabetes and obesity. He left the position as executive vice president of R&D on February 28, 2021, and took the role as CEO of the Novo Nordisk Foundation on March 1, 2021. He has been the president of the Danish Academy of Technical Sciences and has been on the board of directors at the Technical University of Denmark (DTU) and University of Copenhagen. From 2017 to 2020, Thomsen was the chairman of the board of directors at University of Copenhagen. Mads Krogsgaard Thomsen received the royal decoration of Knight of the Order of the Dannebrog by the Danish Royal House on 12 December 2022. In 2024, Thomsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer.
=== Purity and purification === TLC helps show the purity of a sample. A pure sample should only contain one spot by TLC. TLC is also useful for small-scale purification. Because the separated compounds will be on different areas of the plate, a scientist can scrape off the stationary phase particles containing the desired compound and dissolve them into an appropriate solvent. Once all the compound dissolves in the solvent, they filter out the silica particles, then evaporate the solvent to isolate the product. Big preparative TLC plates with thick silica gel coatings can separate more than 100 mg of material. TLC is useful for larger-scale purification and isolation to quickly test solvent mixtures before running flash column chromatography on a large batch of impure material. A compound elutes from a column when the amount of solvent collected is equal to 1/RF. The eluent from flash column chromatography gets collected across several containers (for example, test tubes) called fractions. TLC helps show which fractions contain impurities and which contain pure compound. Furthermore, two-dimensional TLC can help check if a compound is stable on a particular stationary phase. This test requires two runs on a square-shaped TLC plate. The plate is rotated by 90º before the second run. If the target compound appears on the diagonal of the square, it is stable on the chosen stationary phase. Otherwise, it is decomposing on the plate. If this is the case, an alternative stationary phase may prevent this decomposition.
=== Radiation protection associations === The Association of German Radiation Protection Physicians (VDSÄ) was formed in the late 1950s from a working group of radiation protection physicians of the German Red Cross and was founded in 1964. It was dedicated to the promotion of radiation protection and the representation of medical, dental, and veterinary radiation protection concerns to the public and the health care system. In 2017, it was merged into the Professional Association for Radiation Protection. The Austrian Association for Radiation Protection (ÖVS), founded in 1966, pursues the same goals as the Association for Medical Radiation Protection in Austria. The Professional Association for Radiation Protection for Germany and Switzerland is networked worldwide.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.